Questioning the association between bisphosphonates and atypical femoral fractures

Annals of the New York Academy of Sciences

Volumn 1335, Issue 1, 2015, Pages 1-9

  Pazianas, Michael ^a   Kim, Se min ^b   Yuen, Tony ^b   Sun, Li ^b   Epstein, Sol ^b   Zaidi, Mone ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical femur fractures; Bisphosphonates; Femoral shaft fractures; Fragility fractures; Low energy femoral fractures; Subtrochanteric fractures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANIMAL; CHEMICALLY INDUCED; FEMORAL FRACTURES; FOOD AND DRUG ADMINISTRATION; HUMAN; LEGISLATION AND JURISPRUDENCE; OSTEOPOROSIS; RADIOGRAPHY; UNITED STATES;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84920446890     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12551     Document Type: Note

References (47)

1. Pazianas, M., C. Cooper, F.H. Ebetino, et al. 2010. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther. Clin. Risk Manag. 6: 325-343.
2. Pazianas, M. & B. Abrahamsen . 2011. Safety of bisphosphonates. Bone 49: 103-110.
3. Center For Drug Evaluation and Research. 2011. Joint Meeting of the Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees. Adelphi, MD: Transcript. Food and Drug Administration.
4. Odvina, C.V., J.E. Zerwekh, D.S. Rao, et al. 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90: 1294-1301.
5. Kwek, E.B., S.K. Goh, J.S. Koh, et al. 2008. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39: 224-231.
6. Shane, E., D. Burr, P.R. Ebeling, et al. 2010. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25: 2267-2294.
7. Rizzoli, R., K. Akesson, M. Bouxsein, et al. 2011. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos. Int. 22: 373-390.
8. Shane, E., D. Burr, B. Abrahamsen, et al. 2014. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J. Bone Miner. Res. 29: 1-23.
9. Black, D.M., M.P. Kelly, H.K. Genant, et al. 2010. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362: 1761-1771.
10. Meier, R.P., T.V. Perneger, R. Stern, et al. 2012. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch. Intern. Med. 172: 930-936.
11. Schilcher, J., K. Michaelsson & P. Aspenberg . 2011. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364: 1728-1737.
12. Schilcher, J., V. Koeppen, J. Ranstam, et al. 2013. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features: a comparison of 59 cases and 218 controls. Bone 52: 389-392.
13. Giusti, A., N.A. Hamdy, O.M. Dekkers, et al. 2011. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48: 966-971.
14. Feldstein, A.C., D. Black, N. Perrin, et al. 2012. Incidence and demography of femur fractures with and without atypical features. J. Bone Miner. Res. 27: 977-986.
15. Dell, R.M., A.L. Adams, D.F. Greene, et al. 2012. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J. Bone Miner. Res. 27: 2544-2550.
16. Vestergaard, P., F. Schwartz, L. Rejnmark, et al. 2011. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos. Int. 22: 993-1001.
17. Abrahamsen, B., P. Eiken & R. Eastell . 2009. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 24: 1095-1102.
18. Abrahamsen, B., P. Eiken & R. Eastell . 2010. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J. Clin. Endocrinol. Metab. 95: 5258-5265.
19. Park-Wyllie, L.Y., M.M. Mamdani, D.N. Juurlink, et al. 2011. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305: 783-789.
20. Abrahamsen, B. & E.M. Clark . 2012. Disentangling the emerging evidence around atypical fractures. Curr. Rheumatol. Rep. 14: 212-216.
21. Pazianas, M., B. Abrahamsen, Y. Wang & R.G. Russell . 2012. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporos. Int. 23: 2873-2884.
22. Nieves, J.W., J.P. Bilezikian, J.M. Lane, et al. 2010. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos. Int. 21: 399-408.
23. Wang, Z. & T. Bhattacharyya . 2011. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J. Bone Miner. Res. 26: 553-560.
24. Kim, S.Y., S. Schneeweiss, J.N. Katz, et al. 2011. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J. Bone Miner. Res. 26: 993-1001.
25. Somford, M.P., F.W. Draijer, B.J. Thomassen, et al. 2009. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J. Bone Miner. Res. 24: 1736-1740.
26. Armamento-Villareal, R., N. Napoli, K. Diemer, et al. 2009. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif. Tissue Int. 85: 37-44.
27. Puhaindran, M.E., A. Farooki, M.R. Steensma, et al. 2011. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J. Bone Joint Surg. Am. 93: 1235-1242.
28. Neviaser, A.S., J.M. Lane, B.A. Lenart, et al. 2008. Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma. 22: 346-350.
29. Pazianas, M., S. Epstein & M. Zaidi . 2009. Evaluating the antifracture efficacy of bisphosphonates. Rev. Recent Clin. Trials. 4: 122-130.
30. Rodan, G., A. Reszka, E. Golub, et al. 2004. Bone safety of long-term bisphosphonate treatment. Curr. Med. Res. Opin. 20: 1291-1300.
31. Diab, T., M.R. Allen & D.B. Burr . 2009. Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. Osteoporos. Int. 20: 647-652.
32. Mashiba, T., C.H. Turner, T. Hirano, et al. 2001. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524-531.
33. Komatsubara, S., S. Mori, T. Mashiba, et al. 2004. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J. Bone Miner. Res. 19: 999-1005.
34. Allen, M.R., K. Iwata, R. Phipps, et al. 2006. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39: 872-879.
35. Allen, M.R. & D.B. Burr . 2007. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22: 1759-1765.
36. Burr, D.B., T. Diab, A. Koivunemi, et al. 2009. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J. Orthop. Res. 27: 1288-1292.
37. Chapurlat, R.D., M. Arlot, B. Burt-Pichat, et al. 2007. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J. Bone Miner. Res. 22: 1502-1509.
38. Keaveny, T.M., M.R. McClung, X. Wan, et al. 2012. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50: 165-170.
39. Allen, M.R. & D.B. Burr . 2011. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 49: 56-65.
40. Tan, S.C., S.B.J. Koh, S.K. Goh, et al. 2011. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporosis Int. 22: 2211-2212.
41. Roschger, P., A. Lombardi, B.M. Misof, et al. 2010. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). J. Bone Miner. Res. 25: 48-55.
42. Tang, S.Y., M.R. Allen, R. Phipps, et al. 2009. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos. Int. 20: 887-894.
43. Tjhia, C.K., S.M. Stover, D.S. Rao, et al. 2012. Relating micromechanical properties and mineral densities in severely suppressed bone turnover patients, osteoporotic patients, and normal subjects. Bone 51: 114-122.
44. Bala, Y., D. Farlay, R.D. Chapurlat, et al. 2011. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur. J. Endocrinol. 165: 647-655.
45. Lin, J.H., I.W. Chen & D.E. Duggan . 1992. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos. 20: 473-478.
46. Carnevale, V., F. Dicembrino, V. Frusciante, et al. 2000. Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss. J. Nucl. Med. 41: 1478-1483.
47. Israel, O., D. Front, R. Hardoff, et al. 1991. In vivo SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis. J. Nucl. Med. 32: 1157-1161.